Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

A number of other analysts have also issued reports on MRNS. Royal Bank of Canada decreased their target price on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a research report on Friday, October 25th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $0.50 price objective (down previously from $5.00) on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Oppenheimer upgraded Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 target price for the company in a research note on Monday, September 23rd. Truist Financial cut Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. Finally, HC Wainwright reiterated a “neutral” rating and set a $2.00 price objective on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Marinus Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $4.79.

Marinus Pharmaceuticals Trading Down 0.2 %

NASDAQ:MRNS opened at $0.54 on Tuesday. The firm has a market cap of $29.81 million, a price-to-earnings ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a 12-month low of $0.22 and a 12-month high of $10.50. The company’s 50-day moving average is $0.37 and its two-hundred day moving average is $0.99.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC purchased a new position in shares of Marinus Pharmaceuticals in the 2nd quarter valued at $727,000. XTX Topco Ltd acquired a new stake in Marinus Pharmaceuticals in the 2nd quarter valued at $232,000. Point72 DIFC Ltd purchased a new position in Marinus Pharmaceuticals in the second quarter valued at about $28,000. Squarepoint Ops LLC acquired a new position in shares of Marinus Pharmaceuticals during the second quarter worth about $206,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Marinus Pharmaceuticals in the second quarter worth about $64,000. 98.80% of the stock is owned by institutional investors and hedge funds.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.